SCHEMBL6690359

SCHEMBL6690359

CCCC(C(=O)O)C(CCC)C(CC)C(CC)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.41
AKR1A1 P14550 1/20 0.41
CHRM3 P20309 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA2 P00918 1/20 0.36
MAPK1 P28482 1/20 0.36
SLC1A3 P43003 2/20 0.35
SLC1A2 P43004 2/20 0.35
SLC1A1 P43005 2/20 0.35
GRIK1 P39086 1/20 0.33
GRIK2 Q13002 1/20 0.33
ACE2 Q9BYF1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28035948 0.83 CHRM1 (0.50) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL3651519 0.78 CHRM1 (0.52) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL967949 0.78 CHRM1 (0.52) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL3652466 0.78 CHRM1 (0.52) CHRM1AKR1A1CHRM3HTR2AHTR2C
Ethane SCHEMBL29184108 0.76 CHRM1 (0.50) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL4729539 0.76 CHRM1 (0.50) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL30063957 0.76 SLC1A3 (0.41) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL18765448 0.75 TSHR (0.35) TSHR
SCHEMBL14110749 0.75 TDP1 (0.60) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL5031485 0.75 TDP1 (0.60) CHRM1AKR1A1CHRM3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0925792-B1 Insoluble insulin compositions for controlling blood glucose LILLY CO ELI (US) 2004-04-21 EP disclosed
EP-1396272-A1 Insoluble Insulin Compositions for Controlling Blood Glucose Eli Lilly & Company (US) 2004-03-10 EP disclosed
US-20030144181-A1 Insoluble compositions for controlling blood glucose BRADER MARK LAURENCE (US) 2003-07-31 US disclosed
US-6531448-B1 Composition comprising protein selected from insulin, insulin analog, and proinsulin; derivatized protein selected from fatty acid-acylated insulins; complexing compound; hexamer stabilizing compound; and divalent metal cation ELI LILLY AND COMPANY 2003-03-11 US disclosed
US-6465426-B2 ACYLATION ELI LILLY AND COMPANY 2002-10-15 US disclosed
US-20020082199-A1 Insoluble insulin compositions BRADER MARK LAURENCE (US) 2002-06-27 US disclosed
EP-1196445-A1 INSULIN CRYSTALS FOR PULMONARY ADMINISTRATION ELI LILLY AND COMPANY (US) 2002-04-17 EP disclosed
EP-1173482-A1 INSULIN CRYSTALS FOR PULMONARY ADMINISTRATION ELI LILLY AND COMPANY (US) 2002-01-23 EP disclosed
US-20010036916-A1 Insoluble insulin compositions BRADER MARK LAURENCE (US) 2001-11-01 US disclosed
US-6268335-B1 MICROCRYSTAL COMPRISING (A) DERIVIATED INSULIN, DERIVIATED INSULIN ANALOGS, OR DERIVIATED PROINSULINS; (B) A COMPLEXING COMPOUND; (C) A HEXAMER-STABILIZING COMPOUND; AND (D) A DIVALENT METAL CATION. ELI LILLY AND COMPANY 2001-07-31 US disclosed
WO-2001000674-A1 INSULIN CRYSTALS FOR PULMONARY ADMINISTRATION ELI LILLY AND COMPANY (US) 2001-01-04 WO disclosed
WO-2000064940-A1 INSULIN CRYSTALS FOR PULMONARY ADMINISTRATION ELI LILLY AND COMPANY (US) 2000-11-02 WO disclosed
EP-0925792-A2 Insoluble compositions for controlling blood glucose ELI LILLY AND COMPANY (US) 1999-06-30 EP disclosed
WO-1999021578-A1 INSOLUBLE INSULIN COMPOSITIONS ELI LILLY AND COMPANY (US) 1999-05-06 WO disclosed
EP-0911035-A2 INSOLUBLE INSULIN COMPOSITIONS ELI LILLY AND COMPANY (US) 1999-04-28 EP disclosed